Gastrointestinal Very common (10% or more): Nausea (up to 18%), diarrhea (up to 17%) Common (1% to 10%): Vomiting, constipation, dyspepsia, abdominal pain, eructation, flatulence, gastroesophageal reflux disease, abdominal distension Uncommon (0.1% to 1%): Cholelithiasis, acute pancreatitis, increased serum pancreatic amylase levels, increased serum lipase levels, acute gallbladder disease (including cholelithiasis, biliary colic and cholecystectomy) Postmarketing reports : Ileus In pooled placebo-controlled trials, treatment with this drug resulted in mean increases from baseline in serum pancreatic amylase levels of up to 38% and serum lipase levels of up to 42%
Helps regulate appetite, slow digestion, and stimulate insulin
Going beyond, in every step
If your hemoglobin A1c (HbA1c) remains above your individualized targettypically less than 7% for most adults, though targets vary based on age, comorbidities, and hypoglycemia riskafter at least four weeks at your current dose, a dose increase may be warranted
The most common side effects are nausea, fatigue, and mild GI discomfort and they are dose-dependent
.webp)
